Lavergne O - Search Results

1

Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.

Lesueur-Ginot L, Demarquay D, Kiss R, Kasprzyk PG, Dassonneville L, Bailly C, Camara J, Lavergne O, Bigg DC. Lesueur-Ginot L, et al. Among authors: lavergne o. Cancer Res. 1999 Jun 15;59(12):2939-43. Cancer Res. 1999. PMID: 10383158

2

BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.

Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Camara J, Kasprzyk PG, Prévost G, Bigg DC. Demarquay D, et al. Among authors: lavergne o. Cancer Res. 2004 Jul 15;64(14):4942-9. doi: 10.1158/0008-5472.CAN-03-3872. Cancer Res. 2004. PMID: 15256467

3

Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.

Lavergne O, Lesueur-Ginot L, Pla Rodas F, Kasprzyk PG, Pommier J, Demarquay D, Prévost G, Ulibarri G, Rolland A, Schiano-Liberatore AM, Harnett J, Pons D, Camara J, Bigg DC. Lavergne O, et al. J Med Chem. 1998 Dec 31;41(27):5410-9. doi: 10.1021/jm980400l. J Med Chem. 1998. PMID: 9876111

4

[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].

Lavergne O, Bigg DC. Lavergne O, et al. Bull Cancer. 1998 Dec;Spec No:51-8. Bull Cancer. 1998. PMID: 9932086 Review. French.

5

BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.

Lavergne O, Harnett J, Rolland A, Lanco C, Lesueur-Ginot L, Demarquay D, Huchet M, Coulomb H, Bigg DC. Lavergne O, et al. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2599-602. doi: 10.1016/s0960-894x(99)00428-x. Bioorg Med Chem Lett. 1999. PMID: 10498216

6

Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.

Bailly C, Lansiaux A, Dassonneville L, Demarquay D, Coulomb H, Huchet M, Lavergne O, Bigg DC. Bailly C, et al. Among authors: lavergne o. Biochemistry. 1999 Nov 23;38(47):15556-63. doi: 10.1021/bi990947h. Biochemistry. 1999. PMID: 10569939

7

Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.

Philippart P, Harper L, Chaboteaux C, Decaestecker C, Bronckart Y, Gordover L, Lesueur-Ginot L, Malonne H, Lavergne O, Bigg DC, da Costa PM, Kiss R. Philippart P, et al. Among authors: lavergne o. Clin Cancer Res. 2000 Apr;6(4):1557-62. Clin Cancer Res. 2000. PMID: 10778989

8

Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.

Lavergne O, Demarquay D, Bailly C, Lanco C, Rolland A, Huchet M, Coulomb H, Muller N, Baroggi N, Camara J, Le Breton C, Manginot E, Cazaux JB, Bigg DC. Lavergne O, et al. J Med Chem. 2000 Jun 1;43(11):2285-9. doi: 10.1021/jm000129j. J Med Chem. 2000. PMID: 10841808

9

Homocamptothecins: E-ring modified CPT analogues.

Lavergne O, Demarquay D, Kasprzyk PG, Bigg DC. Lavergne O, et al. Ann N Y Acad Sci. 2000;922:100-11. doi: 10.1111/j.1749-6632.2000.tb07029.x. Ann N Y Acad Sci. 2000. PMID: 11193885 Review.

10

The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.

Demarquay D, Coulomb H, Huchet M, Lesueur-Ginot L, Camara J, Lavergne O, Bigg D. Demarquay D, et al. Among authors: lavergne o. Ann N Y Acad Sci. 2000;922:301-2. doi: 10.1111/j.1749-6632.2000.tb07048.x. Ann N Y Acad Sci. 2000. PMID: 11193906 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters